Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ifinatamab deruxtecan + enzalutamide
- Development stage
- Unknown
- Lead developer
- Daiichi Sankyo
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous (ifinatamab Deruxtecan), Oral (enzalutamide)
01
Overview
This is a **combination therapy** composed of ifinatamab deruxtecan, an antibody-drug conjugate (ADC) targeting B7-H3 with a topoisomerase I inhibitor cytotoxic payload, and enzalutamide, a second-generation nonsteroidal antiandrogen that acts as a potent antagonist of the androgen receptor. Ifinatamab deruxtecan binds specifically to B7-H3, a cell surface antigen overexpressed in various solid tumors, leading to intracellular delivery of deruxtecan, which induces DNA damage and apoptosis in tumor cells[1][3][5]. Enzalutamide inhibits androgen receptor signaling, blocking the effects of androgens and arresting growth of androgen-driven prostate cancer cells[2][4][6]. This combination is being studied for the treatment of cancer, with strong evidence for use in small cell lung cancer (SCLC) and prostate cancer.
- Brand names
- Xtandi (enzalutamide)
- Other names
- ifinatamab deruxtecanenzalutamideI-DXd (ifinatamab deruxtecan)
02
Targets
TOP1 (DNA Topoisomerase I)B7-H3AR (Adrenergic receptors)
Beyond the preview
Go deeper on ifinatamab deruxtecan + enzalutamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ifinatamab deruxtecan + enzalutamide.